Anecortave Acetate in Patients With Exudative Age-related Macular Degeneration (AMD)

Anecortave Acetate 15 mg Administered Every 3 Months Versus Anecortave Acetate 15 mg Administered Every 6 Months Versus Anecortave Acetate 30 mg Administered Every 6 Months in Patients With Exudative Age-Related Macular Degeneration (AMD)

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00299507

Enrollment

240

Registered

2006-03-07

Start date

2005-03-31

Completion date

2008-04-30

Last updated

2012-11-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Macular Degeneration

Keywords

exudative AMD, age-related macular degeneration (AMD)

Brief summary

The purpose of this study was to evaluate the effect of the dose concentration and administration frequency of Anecortave Acetate (AA) on visual acuity (VA) and lesion size when administered by posterior juxtascleral depot (PJD) every 3 months (AA 15 mg) or 6 months (AA 15 mg, AA 30 mg) in patients with exudative age-related macular degeneration (AMD).

Interventions

DRUGAnecortave Acetate Sterile Suspension, 30 mg/mL

One 0.5 mL posterior juxtascleral depot injection at 3 or 6 month intervals

DRUGAnecortave Acetate Sterile Suspension, 60 mg/mL

One 0.5 mL posterior juxtascleral depot injection at 6 month intervals

OTHERAnecortave Acetate Vehicle

One 0.5 mL sham injection at 6 month intervals

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

50 Years to No maximum

Healthy volunteers

Inclusion criteria

* Clinical diagnosis of exudative AMD and a primary or recurrent (after laser photocoagulation) subfoveal choroidal neovascularization (CNV) lesion. * Other protocol-defined inclusion criteria may apply.

Exclusion criteria

* Less than 50 years of age. * Other protocol-defined

Design outcomes

Primary

Measure	Time frame
Mean change in best-corrected visual acuity (BCVA) at Month 12 from baseline	Month 12

Secondary

Measure	Time frame
Mean change in lesion growth at Month 12 from baseline	Month 12

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026